ARTICLE | Emerging Company Profile
AviadoBio: ‘Precision microdosing’ of gene therapies to the brain
Led by Zolgensma veteran Deschamps, start-up hopes to bring an FTD program to the clinic next year
December 2, 2021 12:20 AM UTC
With $80 million in new series A funding to move its lead program toward the clinic, AviadoBio believes it can overcome a delivery challenge that will allow it to deploy gene therapies to treat neurodegenerative conditions.
AviadoBio Ltd. is taking a “precision microdosing” approach to treating diseases such as frontotemporal dementia (FTD) and amyotrophic lateral sclerosis, delivering vectors to well-connected “neural hubs” within the CNS, co-founder and Chief Scientific and Clinical Advisor Christopher Shaw told BioCentury...
BCIQ Target Profiles